Johnson & Johnson : advances the next generation of solid tumor therapies with new data at ESMO 2026
In December 2025, Johnson & Johnson completed its acquisition of Halda Therapeutics, adding JNJ-6143 and the RIPTAC platform to its oncology portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results